TABLE 2.

OA Research Priorities, Adapted from a Report from a EULAR ad hoc Expert Committee (148)

Epidemiology	Progressive OA disease course (mechanisms and risk factors, prediction tool for clinical and research purposes, progressor phenotype)
	Early phases in OA development (criteria to define early or pre-OA)
	Criteria to diagnose and classify generalized or multisite OA
	Multidimensionality of OA outcomes (pain, function, participation, performance)
	Foot OA
Pathogenesis	Tissue communication in OA
	Non-cartilage articular pathology
	Mechanisms by which comorbidities influence OA process
	Joint trauma and subsequent repair
	Pathology at earliest stages of OA
	Relationship between pain and structure
Imaging and biomarkers	Performance metrics of imaging and other biomarkers
	Relevance of biomarkers to a broad range of domains
	Defining predictors of progression, especially those that aid targeted interventions (including combining imaging, biomechanical, biochemical biomarkers)
Therapy	Mechanisms of OA pain (origin of pain, its interrelation with other aspects of disease, in order to identify novel targets for pain management)
	Individualized or pathology-targeted therapies (advance knowledge of phenotypes of OA to target specific pharmacological and non-pharmacological therapies)
	Optimal combination therapy strategies (using complex intervention designs comparing monotherapy as well as specific combinations of pharmacological, non-pharmacological, and mixed approaches)